title: Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
abstract: OBJECTIVE
  The molecular pathogenesis of essential thrombocythaemia (ET) is heterogeneous. We aimed to determine the relative sensitivity of four separate molecular assays used to detect the presence of the JAK2 V617F mutation in peripheral blood from patients with essential thrombocythaemia and related myeloproliferative disorders.
  
  
  METHODS
  Purified granulocytes from 60 patients were analysed for the presence of the JAK2 V617F mutation by direct sequencing, denaturing high-performance liquid chromatography (DHPLC), allele-specific polymerase chain reaction (PCR) and allele-specific enrichment. Clinical data were collected for all patients and correlated with assay results.
  
  
  RESULTS
  Direct sequencing and DHPLC were relatively insensitive assays for mutation detection, together identifying only 53% of the JAK2 V617F positive cases of ET. Allele-specific PCR and allele-specific enrichment were significantly more sensitive assays and were able to identify additional ET patients that were positive for the JAK2 V617F mutation in only a minority of circulating granulocytes. Enrichment for the mutation was demonstrated in blood platelets from two of these patients.
  
  
  CONCLUSIONS
  The observed biological difference in circulating granulocyte involvement by the JAK2 V617F clone necessitates a sensitive molecular assay for the diagnostic investigation of thrombocytosis.
authors.affiliation: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. wstevens@nsccahs.health.nsw.gov.au
authors.forename: William S
authors.initials: WS
authors.lastname: Stevenson
authors.forename: Rosemary
authors.initials: R
authors.lastname: Hoyt
authors.forename: Anthony
authors.initials: A
authors.lastname: Bell
authors.forename: Michel
authors.initials: M
authors.lastname: Guipponi
authors.forename: Surender
authors.initials: S
authors.lastname: Juneja
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Grigg
authors.forename: David J
authors.initials: DJ
authors.lastname: Curtis
authors.forename: Hamish S
authors.initials: HS
authors.lastname: Scott
authors.forename: Jeff
authors.initials: J
authors.lastname: Szer
authors.forename: Warren S
authors.initials: WS
authors.lastname: Alexander
authors.forename: Annabel
authors.initials: A
authors.lastname: Tuckfield
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Roberts
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002851:Chromatography, High Pressure Liquid; D004247:DNA / Q000032:analysis / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods*; D005260:Female; D018740:Genetic Heterogeneity; D006098:Granulocytes / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D012680:Sensitivity and Specificity; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D004247:DNA; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2